Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Molecular Partners Expands and Advances Robust Pipeline of DARPin(R) Therapies in Oncology and Ophthalmology
Biotechnology

Molecular Partners Expands and Advances Robust Pipeline of DARPin(R) Therapies in Oncology and Ophthalmology

November 9, 2017 1:00 AM

- Company Begins Development of MP0310, First DARPin® Therapy in Early-stage Immuno-oncology Portfolio - R&D Update and Webcast Today Highlights Continued Progress in Pipeline in Oncology and Ophthalmology ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 9, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announces continued progress...

Read more
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017
BiotechnologyConferenceStudy results

MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017

November 2, 2017 3:15 AM

- Abstract on preliminary data from ongoing phase 2 trial with antibody MOR208 in combination with lenalidomide in relapsed/refractory DLBCL accepted for poster presentation at ASH 2017 - Poster presentation will take place on December 11, 2017, 6:00-8:00pm EST (December 12, 0:00-2:00am CET) - Conference call by MorphoSys scheduled for December 12, 2017, 11:00am EST (5:00pm CET) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2017 /...

Read more
Shareholders of Molecular Partners Approved the Elections of Bill Burns and Patrick Amstutz to the Board of Directors
Biotechnology

Shareholders of Molecular Partners Approved the Elections of Bill Burns and Patrick Amstutz to the Board of Directors

October 31, 2017 11:45 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 31, 2017 / At today's Extraordinary General Meeting of Molecular Partners (SWX: MOLN), the shareholders of the company approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities. The Board of Directors has appointed Bill Burns as Vice-Chairman and will...

Read more
Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer
BiotechnologyChange of PersonnelMiscellaneous

Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer

October 30, 2017 7:05 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 30, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) today announced that Dr. Markus Enzelberger has been appointed as Chief Scientific Officer (CSO), as of November 1, 2017. Dr. Enzelberger has been the Company's Interim CSO since April 15, 2017. He will succeed Dr. Marlies Sproll, who has been on temporary leave from her CSO position for family reasons since April...

Read more
MorphoSys to Host Q3 2017 Conference Call on November 7, 2017
BiotechnologyMiscellaneous

MorphoSys to Host Q3 2017 Conference Call on November 7, 2017

October 26, 2017 8:20 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 26, 2017 / MorphoSys AG (FSE: MOR) ; Prime Standard Segment, TecDAX) will publish its first nine months' 2017 results on November 7, 2017 at 7:00 am CET. At 2:00 pm CET (1:00 pm GMT, 8:00 am EST), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's financial results for the first nine month of 2017 and provide further details on the Company's...

Read more
INTERIM MANAGEMENT STATEMENT Q3 2017: Significant Progress Across All Clinical Programs - New Pre-clinical Immuno-oncology Data to be Presented During R&D Day in New York
Biotechnology

INTERIM MANAGEMENT STATEMENT Q3 2017: Significant Progress Across All Clinical Programs - New Pre-clinical Immuno-oncology Data to be Presented During R&D Day in New York

October 26, 2017 1:00 AM

Research & Development Highlights: - MP0250: Phase 2 Study in Multiple Myeloma Progressing Well and According to Plan - MP0250: FDA Accepted the Company's IND (Submitted in August 2017) for Phase 2 Study Evaluating MP0250 in EGFR-Mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC); - On Track to Dose First Patient in Q1 2018 - MP0274: First Patient Dosed in Phase 1 Trial of This Multi-DARPin® Candidate for the Treatment of HER2-Positive Solid...

Read more
MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
BiotechnologyMiscellaneous

MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL

October 23, 2017 5:06 PM

Designation is Intended to Expedite Development of MorphoSys' Most Advanced Blood Cancer Drug Candidate MOR208 in Combination with Cancer Drug Lenalidomide PLANEGG, MUNICH, GERMANY / ACCESSWIRE / October 23, 2017 / MorphoSys AG (FRA: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MOR208, in combination with lenalidomide, for...

Read more
Qrons Announces Signing of Option Agreement with Dartmouth College
Biotechnology

Qrons Announces Signing of Option Agreement with Dartmouth College

October 20, 2017 7:00 AM

Agreement Will Allow for Further Research Developing Innovative 3D Printable, Biocompatible Materials and Stem Cell Delivery Techniques for Qrons' Traumatic Brain Injury Treatment. Qrons to also Finance Patent Prosecution by Dartmouth MIAMI, FL / ACCESSWIRE / October 20, 2017 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a...

Read more
First Patient Dosed in Phase 1 Clinical Study of Molecular Partners’ Second Proprietary Oncology Asset MP0274
Biotechnology

First Patient Dosed in Phase 1 Clinical Study of Molecular Partners’ Second Proprietary Oncology Asset MP0274

October 12, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 12, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the first patient was dosed in the phase 1 clinical study of its oncology asset, MP0274. MP0274 is a proprietary DARPin® drug candidate for the treatment of HER2-positive cancer with a new mode of action compared to current...

Read more
Pressure BioSciences' Penetration in European Biopharma and High Pressure Markets Continuing to Expand via Multiple Scientific Presentations in Germany, Poland, and Ireland
Biotechnology

Pressure BioSciences' Penetration in European Biopharma and High Pressure Markets Continuing to Expand via Multiple Scientific Presentations in Germany, Poland, and Ireland

October 10, 2017 10:52 AM

SOUTH EASTON, MA / ACCESSWIRE / October 10, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that multiple presentations have highlighted features and benefits of the Company's recently-released, next-generation Barocycler 2320EXTREME...

Read more
Molecular Partners Publishes Invitation to Extraordinary General Meeting to be held on October 31, 2017
Biotechnology

Molecular Partners Publishes Invitation to Extraordinary General Meeting to be held on October 31, 2017

October 9, 2017 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 9, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Extraordinary General Meeting which will be held on Tuesday, October 31, 2017, 2.00 pm CET (doors open at 1.00 pm), at the registered office of the company, 5th floor, Wagistrasse 14, 8952 Schlieren,...

Read more
Bill Burns Nominated for Election to Molecular Partners' Board of Directors as Vice-Chairman with Nomination to Chairman in 2018
Biotechnology

Bill Burns Nominated for Election to Molecular Partners' Board of Directors as Vice-Chairman with Nomination to Chairman in 2018

October 3, 2017 1:00 AM

CEO and Co-founder Patrick Amstutz Also to Stand for Election to Board at Extraordinary General Meeting on October 31, 2017 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 3, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that its Board of Directors has nominated William (Bill) Burns, former CEO of Roche Pharmaceuticals, for...

Read more
Pressure BioSciences, Inc. Issued First Two Patents on Widely-Applicable, High Pressure-Based Ultra Shear Technology (
Biotechnology

Pressure BioSciences, Inc. Issued First Two Patents on Widely-Applicable, High Pressure-Based Ultra Shear Technology ("UST")

October 2, 2017 8:20 AM

Company Believes UST Can Be Used to Create or Improve a Broad Range of Medical, Consumer, and Industrial Products through the Preparation of High-Quality Nanoemulsions and Safe "Clean Label" Food SOUTH EASTON, MA / ACCESSWIRE / October 2, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to...

Read more
Mount Tam Biotechnologies to Present at The MicroCap Conference on October 5th in New York City at the Essex House
Biotechnology

Mount Tam Biotechnologies to Present at The MicroCap Conference on October 5th in New York City at the Essex House

September 28, 2017 11:33 AM

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Mount Tam Biotechnologies (OTC PINK: MNTM) will be presenting at this year's MicroCap Conference on October 5th in New York City. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from...

Read more
MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients
BiotechnologyStudy results

MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients

September 27, 2017 7:35 AM

- Generally well-tolerated with no clinically relevant safety signals in Phase 1 study - At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by week 4 - Results support progression to Phase 2 study - Novel mechanism of action evaluated in patients: MOR106 is the first human monoclonal antibody against IL-17C in clinical development worldwide PLANEGG/MUNICH,...

Read more
ITUS Corporation to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
BiotechnologyConferences

ITUS Corporation to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

September 25, 2017 9:00 AM

NEW YORK, NY / ACCESSWIRE / September 25, 2017 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 2:30 PM EDT/ 11:30 AM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd St. Dr. Amit Kumar, CEO of ITUS, will be presenting, as well as meeting with investors. Each company will be provided with a 30-minute time slot to present to an audience of investors and...

Read more
American CryoStem Secures a Major Contract in Mainland China
BiotechnologyCompany Update

American CryoStem Secures a Major Contract in Mainland China

September 25, 2017 8:00 AM

EATONTOWN, NJ / ACCESSWIRE / September 25, 2017 / American CryoStem Corporation (PINK SHEETS: CRYO) today announced a major transaction in mainland China with Health Innovative Technology of Hong Kong (HIT). After more than two years as CRYO's licensee in Hong Kong, HIT has licensed the patent rights to distribute the Company's ATGRAFT and CELLECT platform in mainland China. To facilitate the expansion, CRYO has extended the licensing and...

Read more
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab) in Psoriatic Arthritis
BiotechnologyStudy

MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with Tremfya(TM) (Guselkumab) in Psoriatic Arthritis

September 21, 2017 7:15 AM

PLANEGG, MUNICH, GERMANY / ACCESSWIRE / September 21, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) has initiated two phase 3 clinical trials to evaluate the efficacy and safety of TremfyaTM (guselkumab) in the treatment of patients with psoriatic arthritis (PsA), a chronic, immune-mediated inflammatory disease affecting both the...

Read more
U.S. Stem Cell Clinic Launches Blog To Educate Consumers On The Power Of Stem Cell Therapy
Biotechnology

U.S. Stem Cell Clinic Launches Blog To Educate Consumers On The Power Of Stem Cell Therapy

September 20, 2017 9:00 AM

SUNRISE, FL / ACCESSWIRE / September 20, 2017 / U.S. Stem Cell Clinic (USCC), a privately-held Florida LLC and leader in novel regenerative medicine solutions and physician-based stem cell therapies for patients, today announced the launch of a new weekly blog to educate consumers on the power of using their body's own healing potential through stem cell therapy. The blog is available at: http://usstemcellclinic.com/blog. "We are in the...

Read more
BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD
Biotechnology

BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD

September 19, 2017 8:17 AM

WEST LAFAYETTE, IN / ACCESSWIRE / September 19, 2017 / Bioanalytical Systems, Inc. (NASDAQ: BASI) ("BASi" or the "Company") today announced the addition of James E. Burleigh as Director of Operations, Preclinical PK/PD. "With his vast experience and impeccable reputation, we are incredibly pleased to have Jim Burleigh join the BASi team," said Philip A. Downing, Senior Vice President of Preclinical Services. "Having worked for BASi before, Jim...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?